1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid, also known as **5-HT2A Receptor Antagonist**, is a research chemical with significant interest due to its potential applications in the treatment of various neurological and psychiatric disorders.
Here's why it's important for research:
**1. Target for Serotonin Receptor Modulation:**
* This compound acts as an antagonist for the 5-HT2A receptor.
* The 5-HT2A receptor is a crucial target for many pharmaceuticals, playing a vital role in regulating various processes like mood, cognition, and sleep.
* By blocking this receptor, 1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid has the potential to influence these processes, leading to therapeutic benefits.
**2. Potential Therapeutic Applications:**
* **Antipsychotic Effects:** 5-HT2A receptors are implicated in schizophrenia, and antagonists like this compound could be useful in treating psychotic symptoms.
* **Antidepressant Effects:** Research suggests that 5-HT2A antagonists may possess antidepressant activity by modulating serotonin signaling.
* **Anxiety Reduction:** 5-HT2A receptors are involved in anxiety disorders, and blocking them may reduce anxiety levels.
* **Migraine Treatment:** Some studies indicate that 5-HT2A antagonists could have a role in managing migraine headaches.
* **Addiction Treatment:** 5-HT2A receptors are involved in drug addiction, and antagonists could be explored for their potential to reduce craving and relapse.
**3. Understanding Neurobiology:**
* This compound serves as a valuable research tool to investigate the role of 5-HT2A receptors in various neurological and psychiatric conditions.
* Studying its effects on these receptors can shed light on the mechanisms underlying these disorders and potentially lead to the development of novel therapeutic strategies.
**Important Considerations:**
* This compound is a research chemical and should be handled with caution.
* Its safety and efficacy in humans are still under investigation, and it is not currently approved for medical use.
* Further research is needed to understand its full therapeutic potential and to optimize its use for clinical applications.
**In summary, 1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid is a research chemical with promising therapeutic potential in various neurological and psychiatric conditions due to its activity on the 5-HT2A receptor. Further research will determine its ultimate role in treating these disorders.**
ID Source | ID |
---|---|
PubMed CID | 652490 |
CHEMBL ID | 1460713 |
CHEBI ID | 108491 |
SCHEMBL ID | 1921552 |
Synonym |
---|
BB 0260235 |
smr000011511 |
MLS000032596 , |
CBDIVE_001203 |
CHEMDIV1_012767 |
1-benzo[1,3]dioxol-5-yl-2,3,4,9-tetrahydro-1h-beta-carboline-3-carboxylic acid |
CHEBI:108491 |
AKOS000300725 |
HMS623E07 |
1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid |
HMS2470N07 |
CCG-33370 |
AKOS016194003 |
SCHEMBL1921552 |
CHEMBL1460713 |
Q27187374 |
SR-01000552174-1 |
sr-01000552174 |
82789-26-2 |
1-(2h-1,3-benzodioxol-5-yl)-1h,2h,3h,4h,9h-pyrido[3,4-b]indole-3-carboxylic acid |
1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1h-beta-carboline-3-carboxylic acid |
STL508442 |
BRD-A21023809-001-10-6 |
1h-pyrido[3,4-b]indole-3-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro- |
1-(benzo[d][1,3]dioxol-5-yl)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid |
CS-0322385 |
SY320359 |
NCGC00032946-02 |
DTXSID001128457 |
Class | Description |
---|---|
harmala alkaloid | Any member of a class of naturally occurring alkaloids based on a 1-methyl-9H-beta-carboline skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 15.8489 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 10.6917 | 88.5700 | AID887 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 100.0000 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 100.0000 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |